<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vilobelimab (United States: Authorized for use): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vilobelimab (United States: Authorized for use): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vilobelimab (United States: Authorized for use): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="141244" href="/d/html/141244.html" rel="external">see "Vilobelimab (United States: Authorized for use): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58763102"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Shelf-Life Extension for Gohibic</span>
<span class="collapsible-date">October 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has authorized an extension to the shelf-life of certain lots of Gohibic (vilobelimab) from 24 to 30 months when stored at 2°C to 8°C (36°F to 46°F).</p>
<p style="text-indent:0em;">Further information, including lot numbers and extended expiry dates, can be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Femergency-preparedness-and-response%2Fmcm-legal-regulatory-and-policy-framework%2Fexpiration-dating-extension%23COVIDtherapeutics&amp;token=4l1d118uNDtupkRojpm4fEEkTfYQvm3waOEEhSrkhnTfuypOuc8Fb8ci0JsPf9YmbhBkzGctQ%2BJ5Tzc1s2KInkS9L1jEinHDNcEnf9bSZ2ALfIaUHbsAH0nAb8QshkJktHP%2F2Pc1wX%2F6xu4Y%2B8fBo7WWpdGOy8%2FXArnKLyUkbao%3D&amp;TOPIC_ID=141200" target="_blank">https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/expiration-dating-extension#COVIDtherapeutics</a>.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58339129"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gohibic</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58037558"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Complement C5a Inhibitor;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F58058015"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9116062-427d-4715-8eda-5d582e2630c5">COVID-19, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 800 mg once on day 1 (within 48 hours of intubation), followed by 800 mg once daily on days 2, 4, 8, 15, and 22, as long as the patient remains hospitalized (even if discharged from the ICU) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-36087611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-36087611'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F58058017"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F58058018"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F58058016"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F58745337"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Infections</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Vilobelimab is associated with an increased risk of <b>serious infection</b>, including bacterial <b>pneumonia</b> and <b>sepsis. </b>When adjusted for hospital length of stay, the incidence of serious infections and sepsis were statistically similar between treatment and placebo groups, although pneumonia occurred more frequently in patients treated with vilobelimab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged hospitalization (&gt;15 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F58057131"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from the FDA issued emergency use authorization (EUA), unless otherwise specified. Refer to EUA for information regarding reporting adverse reactions (FDA 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pulmonary embolism (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (22%)<span class="lexi-table-link-container"> (<a aria-label="Sepsis table link" class="lexi-table-link" data-table-id="lexi-content-sepsis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sepsis')">table 1</a>)</span><span class="table-link" style="display:none;">Sepsis</span>, serious infection (33%)<span class="lexi-table-link-container"> (<a aria-label="Serious Infection table link" class="lexi-table-link" data-table-id="lexi-content-serious-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-serious-infection')">table 2</a>)</span><span class="table-link" style="display:none;">Serious Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sepsis" frame="border" id="lexi-content-sepsis" rules="all">
<caption style="text-align:center;">
<b>Vilobelimab: Adverse Reaction: Sepsis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Vilobelimab) + Standard of Care</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo + Standard of Care</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vilobelimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">175</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">189</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Serious Infection" frame="border" id="lexi-content-serious-infection" rules="all">
<caption style="text-align:center;">
<b>Vilobelimab: Adverse Reaction: Serious Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Vilobelimab) + Standard of Care</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo + Standard of Care</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vilobelimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">175</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">189</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delirium (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (31%)<span class="lexi-table-link-container"> (<a aria-label="Pneumonia table link" class="lexi-table-link" data-table-id="lexi-content-pneumonia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pneumonia')">table 3</a>)</span><span class="table-link" style="display:none;">Pneumonia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pneumonia" frame="border" id="lexi-content-pneumonia" rules="all">
<caption style="text-align:center;">
<b>Vilobelimab: Adverse Reaction: Pneumonia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Vilobelimab) + Standard of Care</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo + Standard of Care</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vilobelimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">175</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">189</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Deep vein thrombosis (6%), hypertension (9%), supraventricular tachycardia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (6%), infection due to enterococcus (6%), septic shock (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hypoxia (5%), pneumothorax (8%), pulmonary aspergillosis (6%), pulmonary complications (pneumomediastinum: 5%), respiratory tract infection (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hemodynamic deterioration</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Eczema</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Multi-organ failure</p></div>
<div class="block coi drugH1Div" id="F58037561"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58057998"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity reactions have been observed with administration of vilobelimab (FDA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Serious infections due to bacterial, fungal, and viral pathogens have been reported in patients with COVID-19 receiving vilobelimab. Consider the risk/benefits of treatment with vilobelimab in patients with COVID-19 and other concurrent infections (FDA 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium: Some products may contain sodium.</p></div>
<div class="block prod-avail drugH1Div" id="F58037549"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Investigational agent; approved for emergency use authorization by the FDA in April 2023.</p></div>
<div class="block foc drugH1Div" id="F58339130"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gohibic: 200 mg/20 mL (20 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F58339128"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block accres drugH1Div" id="F58057995"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Vilobelimab is not commercially available; it is available as part of ongoing clinical trials and through an emergency use authorization (EUA) from the FDA.</p>
<p style="text-indent:0em;margin-top:2em;">As part of the EUA, fact sheets pertaining to emergency use of vilobelimab are required to be available for health care providers and patients/caregivers, and certain mandatory requirements for vilobelimab administration under the EUA must be met as outlined in the FDA EUA letter; the fact sheets and EUA letter may be accessed at https://www.gohibic.com. Additionally, health care providers must track and report all medication errors and serious adverse events potentially associated with vilobelimab use by submitting FDA Form 3500 (health professional, available at: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-forms-fda-safety-reporting%2Finstructions-completing-form-fda-3500&amp;token=JawecUzmcWoycZF2aiaddFxIves895jp9lZnR66bz83WN1VdAJfKm2uDiFTzGKZvRVWk827gL5rCvQqtlXj0ONBs3Pf7poW87Tbg8WYt%2FfzGssLuYYtX1iG0rPt5gSzB&amp;TOPIC_ID=141200" target="_blank">https://www.fda.gov/safety/medwatch-forms-fda-safety-reporting/instructions-completing-form-fda-3500</a>) online (<a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-fda-safety-information-and-adverse-event-reporting-program&amp;token=xvyaImDcLZQw%2FKZaoXWwxUDhBq6SPMBQbzrmFLdvw6uLInTYq0WEZZE23nYfEJdpji3bziSW87ksfkpGSKeZ%2FC4BVOKV%2FWdosDZdfOoBdep7W5s6oZowZkx4dccnetNU&amp;TOPIC_ID=141200" target="_blank">www.fda.gov/medwatch/report.htm</a>), by mail (MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787) or fax (1-800-FDA-0178), or by calling 1-800-FDA-1088 to request a reporting form; a copy of all forms should also be provided to InflaRx GmbH (phone: 1-888-254-0602; fax: 1-866-728-2630; email: <a class="__cf_email__" data-cfemail="770701020416371e19111b16050f591312" href="/cdn-cgi/l/email-protection">[email protected]</a>).</p></div>
<div class="block adm drugH1Div" id="F58058019"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> If diluted solution is refrigerated prior to administration, allow to come to room temperature prior to administration. Administer as an IV infusion in a dedicated IV line over 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F58037560"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">See “Use: Off-Label.”</p></div>
<div class="block off-label drugH1Div" id="F58037601"><span class="drugH1">Use: Off-Label: Adult</span><p>COVID-19, treatment</p></div>
<div class="block mst drugH1Div" id="F58057993"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Vilobelimab may be confused with belimumab, vilazodone, or viloxazine.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58065138"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58065135"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F58057996"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Vilobelimab is a chimeric human/mouse immunoglobulin (IgG<sub>4</sub>) antibody. Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p></div>
<div class="block brc drugH1Div" id="F58057997"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if vilobelimab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Vilobelimab is a chimeric human/mouse immunoglobulin (IgG<sub>4</sub>) antibody. Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F58058022"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of new infection during and after treatment.</p></div>
<div class="block pha drugH1Div" id="F58058012"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vilobelimab is a chimeric human/mouse monoclonal IgG4-kappa antibody that binds to C5a and blocks its interaction with the C5a receptor. C5a is part of the complement system and is activated as part of the innate immune response, initiating an inflammatory cascade that includes increased vascular permeability, coagulation, proinflammatory cytokine release, and recruitment and activation of neutrophils and other myeloid cells (FDA 2023).</p></div>
<div class="block phk drugH1Div" id="F58058013"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Half-life elimination: 95 hours.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vilobelimab-united-states-authorized-for-use-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vilobelimab-united-states-authorized-for-use-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies.<i> Clin Dev</i>
<i>Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vilobelimab-united-states-authorized-for-use-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vilobelimab-united-states-authorized-for-use-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Emergency use authorization (EUA) for vilobelimab (IFX-1) – Center for Drug Evaluation and Research (CDER) review. <a href="https://www.fda.gov/media/167044/download?attachment" target="_blank">https://www.fda.gov/media/167044/download?attachment</a>. Updated September 29, 2022. Accessed October 20, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vilobelimab-united-states-authorized-for-use-drug-information/abstract-text/FDA.2/pubmed" id="FDA.2" target="_blank">FDA.2</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). Fact sheet for healthcare providers: Emergency Use Authorization (EUA) for Gohibic. <a href="https://www.fda.gov/media/166824/download" target="_blank">https://www.fda.gov/media/166824/download</a>. Published April 2023. Accessed April 5, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vilobelimab-united-states-authorized-for-use-drug-information/abstract-text/FDA.1/pubmed" id="FDA.1" target="_blank">FDA.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36087611">
<a name="36087611"></a>Vlaar APJ, Witzenrath M, van Paassen P, et al; PANAMO study group. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Respir Med</i>. 2022;10(12):1137-1146. doi:10.1016/S2213-2600(22)00297-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vilobelimab-united-states-authorized-for-use-drug-information/abstract-text/36087611/pubmed" id="36087611" target="_blank">36087611</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 141200 Version 20.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
